|
US2013184280A1
|
|
Substituted thiazoles as vegfr2 kinase inhibitors
|
|
AU2012321104A1
|
|
Amphorous ezatiostat ansolvate
|
|
AU2012251062A1
|
|
Excipient compatibility with ezatiostat
|
|
US2013035389A1
|
|
Methods for treating myelodysplastic syndrome with ezatiostat
|
|
CA2829130A1
|
|
Ezatiostat for treating multiple myeloma
|
|
MX2011009305A
|
|
Compositions and methods for treating myelodysplastic syndrome.
|
|
MX2011009302A
|
|
Compositions and methods for treating myelodysplastic syndrome.
|
|
MX2011009301A
|
|
Compositions and methods for treating myelodysplastic syndrome.
|
|
KR20130020944A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
KR20130020943A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
KR20130020945A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
BRPI1103978A2
|
|
compositions and methods for treating myelodysplastic syndrome
|
|
TW201306834A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
TW201306832A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
TW201306831A
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
WO2013019222A1
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
WO2013019220A1
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
WO2013019221A1
|
|
Compositions and methods for treating myelodysplastic syndrome
|
|
EP2392341A1
|
|
Compositions for use in treating myelodysplastic syndrome
|
|
EP2392330A1
|
|
Compositions for use in treating myelodysplastic syndrome
|
